We are live on ! Find out more
Abingworth

Abingworth Portfolio holdings

AUM $304M Turnover 0%
1-Year Est. Return 95.02%
This Fund
S&P 500
This Quarter Est. Return
+40.84%
1 Year Est. Return
+95.02%
3 Year Est. Return
+186.67%
5 Year Est. Return
+346.26%
10 Year Est. Return
–
AUM
$175M
AUM Growth
+$14.2M
Cap. Flow
-$31.4M
Cap. Flow %
-17.91%
Top 10 Hldgs %
92.73%
Holding
17
New
1
Increased
2
Reduced
1
Closed
1
Avg Time Held
1.9 years
Top 10 Avg Time Held
1.8 years
Top 20 Avg Time Held
1.9 years

Top Sells

Rank Stock Value
1
CRSP icon
CRISPR Therapeutics
CRSP
+$37M
2
DERM icon
Dermira
DERM
+$559K

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow Held Since
CRSP icon
1
CRISPR Therapeutics
CRSP
$3.89B
$72.7M 41.53%
1,237,202
-650,000
-34% -$37M
2016 Q4
6 quarters
SIEN
2
DELISTED
Sientra
SIEN
$48.3M 27.6%
248,049
+28,148
+13% +$4.46M
2014 Q4
14 quarters
PRTK
3
DELISTED
Paratek Pharmaceuticals
PRTK
$10.6M 6.04%
1,041,131
– –
2014 Q4
14 quarters
OBSV
4
DELISTED
ObsEva
OBSV
$6.66M 3.81%
440,000
– –
2017 Q3
3 quarters
ONCT icon
5
DELISTED
Oncternal Therapeutics
ONCT
$5.2M 2.97%
2,423
– –
2017 Q3
3 quarters
TARA icon
6
Protara Therapeutics
TARA
$147M
$4.84M 2.77%
50,447
– –
2014 Q4
14 quarters
SRRA
7
DELISTED
Sierra Oncology
SRRA
$4.28M 2.44%
36,111
– –
2018 Q1
1 quarter
CBAY icon
8
DELISTED
Cymabay Therapeutics
CBAY
$3.67M 2.09%
273,417
– –
2015 Q3
11 quarters
CHMA
9
DELISTED
Chiasma
CHMA
$3.12M 1.78%
2,080,595
– –
2015 Q3
11 quarters
ADAP
10
DELISTED
Adaptimmune Therapeutics
ADAP
$2.96M 1.69%
250,000
– –
2015 Q4
10 quarters
RARE icon
11
Ultragenyx Pharmaceutical
RARE
$1.7B
$2.93M 1.67%
38,100
– –
2017 Q3
3 quarters
CLLS icon
12
Cellectis
CLLS
$107M
$2.82M 1.61%
100,000
– –
2015 Q4
10 quarters
AUPH icon
13
Aurinia Pharmaceuticals
AUPH
$2.06B
$2.25M 1.29%
400,434
+148,305
+59% +$827K
2017 Q1
5 quarters
OCGN icon
14
Ocugen
OCGN
$257M
$2.2M 1.26%
14,815
– –
2016 Q3
7 quarters
IMDZ
15
DELISTED
Immune Design
IMDZ
$1.62M 0.93%
352,300
– –
2016 Q2
8 quarters
AVEO
16
DELISTED
AVEO Pharmaceuticals
AVEO
$900K 0.51%
+40,000
New +$948K
2018 Q2
0 quarters
DERM icon
17
DELISTED
Dermira
DERM
– –
-70,000
Closed -$559K –

Similar funds

Abingworth's Q2 2018 Portfolio in Review

As of Q2 2018, Abingworth held 17 positions worth $175M, up 8.8% from $161M the previous quarter. Its ten largest holdings account for 93% of the portfolio.

Abingworth withdrew a net $31.4M in Q2 2018, closing 1 position and reducing 1 holding. Its most notable exit was Dermira, an estimated $559K position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

Against the trend, Abingworth opened a new position in AVEO Pharmaceuticals worth $900K.

  • Abingworth's largest Q2 2018 buy was AVEO Pharmaceuticals: 40,000 shares worth $900K.
  • Abingworth added most to Sientra in Q2 2018, an estimated $4.46M increase.
  • Abingworth's biggest Q2 2018 reduction was CRISPR Therapeutics, cutting an estimated $37M.
  • Abingworth fully exited Dermira in Q2 2018, selling an estimated $559K.
  • Abingworth's ten largest holdings make up 93% of its $175M portfolio in Q2 2018.
  • Abingworth opened 1 new position and closed 1 in Q2 2018.
  • Abingworth's portfolio value rose 8.8% quarter-over-quarter to $175M.

Based on Abingworth's 13F filing for Q2 2018, filed 14 Aug 2018.